NCT04069052View on ClinicalTrials.gov

The Effect of Inhaled Nitric Oxide on Deadspace in COPD

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Nitric Oxide

Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.

DRUG

Placebo

Room air (placebo) flowed into a mask and breathed in.

Trial Locations (1)

K7L 2V7

Respiratory Investigation Unit, Kingston General Hospital, Kingston

All Listed Sponsors
lead

Dr. Denis O'Donnell

OTHER

NCT04069052 - The Effect of Inhaled Nitric Oxide on Deadspace in COPD | Biotech Hunter | Biotech Hunter